Laos version of imitation Adagraxi cloth price

Adagrasib is an oral drug that belongs to a new class of anti-tumor drugs, known as KRAS G12C inhibitors. Its mechanism of action is to inhibit the growth and spread of cancer cells by targeting the G12C mutation in the KRAS gene. KRAS G12C mutation is a common cancer mutation, especially in advanced non-small cell lung cancer (NSCLC).

Since adagrasib is not yet available on the domestic market, patients are currently unable to purchase it directly domestically and must obtain it through overseas channels. The price of the original Adagrasibu drug produced in the United States is extremely high, reaching more than 180,000 yuan, making it unaffordable for ordinary families.

But what is gratifying is that foreign generic drugs have recently come out. Among them, the generic drug of adagrasibu launched by Lucius Pharmaceuticals in Laos is relatively affordable, priced at about four to five thousand yuan per box, and its pharmaceutical ingredients are basically the same as the original drug.

The targeting effect of adagrasib enables it to more precisely intervene in the biological processes of cancer cells, and has lower toxic and side effects than traditional chemotherapy drugs. This makes adagrasib an innovative option for the treatment of tumors associated with KRAS G12C mutations.

Clinical trials have shown that adagrasib has shown good efficacy in some patients, including shrinking tumors and prolonging survival. However, patient response to adagrasib may vary from individual to individual, so detailed evaluation and monitoring is required before use.

Overall, adagrasib represents an innovative advance in a personalized treatment strategy targeting specific tumor mutations, providing new hope for patients for whom conventional treatments are ineffective or unsuitable. With further research on its mechanism of action and clinical application, adagrasib is expected to become one of the important drugs in the field of tumor treatment.